GNLX:NASDAQ
Genelux Corp
2,54 USD
arrow_downward
−0,59%(−0,015) 1D
12. lis, 16:00:01 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za GNLX...
Otvori
2,59 USD
Najviša
2,59 USD
Najniža
2,51 USD
Trž. kap.
115,15 mil.
Prosj. kol.
260,79 tis.
Količina
72,62 tis.
52-tjed. najviša
8,54 USD
52-tjed. najniža
2,29 USD
EPS
−0,87 USD
Beta
0,59
Dionice u optjecaju
45,24 mil.
Broj djelatnika
26
Otvori
2,59 USD
Najviša
2,59 USD
Najniža
2,51 USD
Trž. kap.
115,15 mil.
Prosj. kol.
260,79 tis.
Količina
72,62 tis.
52-tjed. najviša
8,54 USD
52-tjed. najniža
2,29 USD
EPS
−0,87 USD
Beta
0,59
Dionice u optjecaju
45,24 mil.
Broj djelatnika
26
Vijesti
Iz web-izvora i od partnera za vijesti
www.dars.gov.et
·
prije 1 mjesec
GNLX Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical Investment - Earnings Yield Analysis
Profil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Genelux Corp – informacije
Glavni izvršni direktor-
Zaposlenici26
Osnovano2001
SjedišteWestlake Village, Kalifornija, Sjedinjene Američke Države
Sektor-
Web-lokacijagenelux.com